Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

Mehran Afshar,H. Patel,Ankit Jain,Abhishek Kumar,Prashant Patel,Nicholas D. James,Emilio Porfiri

Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

2019

Mehran Afshar
H. Patel
Ankit Jain
Abhishek Kumar
Prashant Patel
Nicholas D. James
Emilio Porfiri

ABSTRACTBackground: Patients with metastatic renal cell carcinoma (mRCC) are commonly treated with tyrosine kinase inhibitors (TKIs). An adverse effect frequently suffered by patients is lethargy, ...

Keywords:

Immunology
Cancer research
Tyrosine-kinase inhibitor
Adverse effect
Renal cell carcinoma
Medicine
Oncology
Cohort
Internal medicine
Testosterone
Lethargy
Odds ratio
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations